Data Supports Biomarker-Driven Strategy for Development of ICOS Agonist Antibody, JTX-2011
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that preclinical data supporting its Translational Science Platform and biomarker driven strategy will be presented during the pre-conference program and in a poster session at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held November 8-12, 2017 in National Harbor, Maryland.
“The identification of predictive biomarkers throughout our discovery and clinical development process is a foundational aspect of Jounce's Translational Science Platform,” said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. “Our investment in translational science approaches and technologies, including the preclinical histoculture techniques and data presented at SITC, continue to inform our JTX-2011 clinical development program.”
Details on the presentations are below:
A biomarker-driven approach for the development of the ICOS agonist antibody, JTX-2011
Session Title: Immuno-Oncology Biomarkers: Today’s Imperatives for Tomorrow’s Needs
Presenter: Heather Hirsch, Ph.D., Director of Translational Genomics
Location: Cherry Blossom Ballroom
Date and Time: Wednesday, November 8, 2017; 8:45am–8:55am ET
The oral presentation will include preclinical data validating the use of Jounce’s biomarker driven strategy to guide the clinical development program of JTX-2011. The presentation will also demonstrate how the Translational Science Platform is used to identify potential predictive biomarkers, to prioritize indications based on levels of these specific biomarkers and to help match the right immunotherapy to the right patient.
Use of ex vivo Histoculture to identify potential predictive biomarkers for the ICOS agonist antibody, JTX-2011
Poster Session: Poster #39
Session Title: Biomarkers and Immune Monitoring
Location: Prince George Exhibit Hall, Section DE
Date and Time: Friday, November 10, 2017; 12:30pm–2pm ET and 6:30pm–8pm ET
The poster presentation shows the exploration of additional potential predictive biomarkers using ex vivo tumor histoculture, which can facilitate a functional analysis of therapies using intact human tumor tissue. The data indicate that ex vivo histoculture is a robust tool that can be used to assess candidate predictive biomarkers, identify potential biomarkers and interrogate post-dose responses to novel therapeutics.
Presentation and poster will be available on the Investors and Media section of the Jounce Therapeutics website under “Presentations & Publications” at www.jouncetx.com.
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells. Preclinical data support that JTX-2011 may have a dual mechanism of action that stimulates anti-tumor T effector cells, and also reduces the immunosuppressive T regulatory cells in the tumor microenvironment. The company is developing JTX-2011 to treat solid tumors as a single agent and in combination with other therapies.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in the Phase 2 portion of the Phase 1/2 ICONIC trial. For more information, please visit www.jouncetx.com.
Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc.
Pure Communications, Inc.